Spherix’s tracking data reveals use of Dupixent in EoE has tripled since its’ approval. EXTON, Pa., April 3, 2023 /PRNewswire/ — In 2017, Sanofi/Regeneron announced the FDA approval for the first biologic agent to treat atopic dermatitis (AD). The success of that drug, Dupixent…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.